Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Xl092
2. 2367004-54-2
3. Jun04542
4. Xl-092
5. Cl-092
6. Zanzalintinib [inn]
7. Unii-kc2jc2za04
8. Kc2jc2za04
9. Schembl21200856
10. Xl 092 [who-dd]
11. Gtpl12093
12. Ex-a5029
13. Nsc828252
14. Nsc-828252
15. Compound 8 [wo2019148044a1]
16. Ac-36753
17. Hy-138696
18. Cs-0167112
19. 1,1-cyclopropanedicarboxamide, N-(4-fluorophenyl)-n'-(4-((7-methoxy-6-((methylamino)carbonyl)-4-quinolinyl)oxy)phenyl)-
20. 1-n'-(4-fluorophenyl)-1-n-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide
21. N-(4-fluorophenyl)-n'-(4-((7-methoxy-6- (methylcarbamoyl)quinolin-4- Yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide
| Molecular Weight | 528.5 g/mol |
|---|---|
| Molecular Formula | C29H25FN4O5 |
| XLogP3 | 4.7 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 528.18089807 g/mol |
| Monoisotopic Mass | 528.18089807 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 885 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Encoberminogene Rezmadenovec manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Encoberminogene Rezmadenovec, including repackagers and relabelers. The FDA regulates Encoberminogene Rezmadenovec manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Encoberminogene Rezmadenovec API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Encoberminogene Rezmadenovec supplier is an individual or a company that provides Encoberminogene Rezmadenovec active pharmaceutical ingredient (API) or Encoberminogene Rezmadenovec finished formulations upon request. The Encoberminogene Rezmadenovec suppliers may include Encoberminogene Rezmadenovec API manufacturers, exporters, distributors and traders.
Encoberminogene Rezmadenovec Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Encoberminogene Rezmadenovec GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Encoberminogene Rezmadenovec GMP manufacturer or Encoberminogene Rezmadenovec GMP API supplier for your needs.
A Encoberminogene Rezmadenovec CoA (Certificate of Analysis) is a formal document that attests to Encoberminogene Rezmadenovec's compliance with Encoberminogene Rezmadenovec specifications and serves as a tool for batch-level quality control.
Encoberminogene Rezmadenovec CoA mostly includes findings from lab analyses of a specific batch. For each Encoberminogene Rezmadenovec CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Encoberminogene Rezmadenovec may be tested according to a variety of international standards, such as European Pharmacopoeia (Encoberminogene Rezmadenovec EP), Encoberminogene Rezmadenovec JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Encoberminogene Rezmadenovec USP).
LOOKING FOR A SUPPLIER?
